Pahr Therapeutics, Inc. has raised $14 million in seed funding to support its work in developing new treatments for pulmonary arterial hypertension (PAH) — a serious lung disease. The funding round was led by RA Capital Management, AN Venture Partners, and University of Tokyo Edge Capital Partners (UTEC).
As part of the funding round, three new members have joined Pahr Therapeutics’ board of directors: Dr. Andrew Levin from RA Capital Management, Ken Horne from AN Venture Partners and Dr. Atsushi Usami from UTEC. Their combined expertise in biotech investment and company building will support Pahr’s mission to develop innovative treatments for pulmonary arterial hypertension (PAH).
Pahr Therapeutics was incubated at Raven, the startup incubator of RA Capital Management, and is led by Neil Buckley, a Venture Partner at Raven. Dr. Co-founded the company. Yoshikazu Nakaoka, Makoto Okazawa, and Ryotaro Asano from the National Cerebral and Cardiovascular Center (NCVC) in Osaka, Japan.
Dr. Nakaoka, who heads the Vascular Physiology Department at NCVC has led groundbreaking research into the molecular causes of pulmonary arterial hypertension (PAH). His work and insights have played a key role in shaping Pahr Therapeutics innovative approach to developing new treatments for PAH.
“I am excited to work with RA Capital Management, AN Venture Partners, and UTEC to bring much-needed new therapies to PAH patients,” said Dr. Nakaoka. “Having global investors support the company is inspiring for us, and we look forward to advancing into clinical studies early next year.”
Dr. Nakaoka was a finalist at Science2Startup Japan in 2024, and working with mentor Andrew Levin helped lead to the formation of Pahr Therapeutics.
Pahr Therapeutics is a clinical-stage company working on new ways to treat pulmonary arterial hypertension (PAH), a serious lung condition. It was started by researchers from the National Cerebral and Cardiovascular Center (NCVC) in Osaka, Japan, and got its early support from Raven, the startup incubator of RA Capital Management.
Read more- Olivery Raises Seed Funding from Ibtikar Fund and Flat6Labs
